Equities

Todos Medical Ltd

TOMDF:QBB

Todos Medical Ltd

Actions
  • Price (USD)0.0125
  • Today's Change0.000 / 0.81%
  • Shares traded647.78k
  • 1 Year change-54.55%
  • Beta-1.5430
Data delayed at least 15 minutes, as of May 25 2022 20:40 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Todos Medical Ltd is a Israel-based clinical-stage in-vitro diagnostics company focused on the development of blood tests for the early detection of cancer. The Companys Total Biochemical Infrared Analysis (TBIA) platform, represents a method for cancer screening of solid tumors using peripheral blood spectroscopy analysis. The process involves observing the immune system’s response to tumor presence. TBIA analyzes the entire biochemical signatures spectrum including proteins, lipids, nucleic acids and carbohydrates of effected immune cells from peripheral blood, using infrared spectroscopy.

  • Revenue in USD (TTM)12.23m
  • Net income in USD-43.31m
  • Incorporated2010
  • Employees7.00
  • Location
    Todos Medical Ltd121 Derech Menachem Begin, 30th FloorTEL AVIV-YAFO 6701203IsraelISR
  • Phone+972 86333964
  • Fax+972 39726001
  • Websitehttp://www.todosmedical.com
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
TOMDF:QBB since
announced
Transaction
value
Nlc Pharma Inc-3cl Protease AssetsAnnounced29 Nov 202129 Nov 2021Announced-84.38%--
Data delayed at least 15 minutes, as of May 25 2022 20:40 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Neurobo Pharmaceuticals Inc0.00-14.84m13.54m5.00--1.14-----0.6127-0.61270.000.44740.00----0.00-107.42-145.22-117.83-213.74------------0.00------48.50------
Windtree Therapeutics Inc0.00-66.80m13.56m33.00--0.3781-----2.48-2.480.001.220.00----0.00-65.81-41.99-70.04-48.82-------4,801.38---716.230.3016-------107.69---0.1428--
Stealth BioTherapeutics Corp0.00-52.53m13.83m38.00---------0.9186-0.91860.00-0.76330.00----0.00-122.05-252.61-193.84-3,132.08-------1,713.54---7.54--------8.58---25.29--
Protect Pharmaceutical Corp0.00-15.04k13.85m3.00---------0.0135-0.01350.00-0.13640.00-------149.88-22,566.05---------------0.0495---------193.96------
Hoth Therapeutics Inc0.00-12.62m13.85m4.00--1.31-----0.5285-0.52850.000.32890.00----0.00-84.33---89.05--------------0.00-------98.86------
American Cryostem Corp-44.82k-3.21m13.99m6.00---------0.0541-0.0541-0.0008-0.0329-0.03281.26---7,470.00-234.95-133.78-1,986.23----75.68---202.990.1932-19.02-----96.31-48.95-144.18--9.22--
Smart for Life Inc-100.00bn-100.00bn14.04m--------------------------------------------------------------
Artelo Biosciences Inc0.00-10.14m14.12m4.00--0.5479-----0.3419-0.34190.000.60940.00----0.00-50.49---52.41-------------759.090.00--------------
Todos Medical Ltd12.23m-43.31m14.25m7.00------1.17-0.0618-0.06180.0181-0.0248-----------588.27----35.84---354.15-504.870.3474-0.29024.11--134.88---45.48------
Exicure Inc1.09m-59.97m14.32m40.00--4.42--13.20-0.651-0.6510.01120.02640.0167----23,085.11-92.38-47.29-125.31-61.57-----5,527.47-548.45---32.060.00---102.91---159.86--19.69--
LogicBio Therapeutics Inc7.77m-36.41m14.42m62.00--0.5788--1.86-1.12-1.120.2380.75570.1234--174.49125,241.90-57.87-49.03-71.67-53.74-----468.89-1,536.49---35.350.2318--56.63---22.71--29.35--
Endexx Corp776.32k-7.37m14.51m--------18.69-0.0156-0.01560.0016-0.02190.35680.786512.41---338.52------0.9725---948.72--0.0241-3.51-----43.43--25.70------
Petros Pharmaceuticals Inc7.81m-8.99m14.51m24.00--0.4083--1.86-0.8252-0.82520.77581.720.11382.502.05325,469.20-13.10---27.92--79.52---115.05--0.9691--0.00---18.29--56.35------
Healthy Extracts Inc1.76m-690.48k14.57m----5.96--8.29-0.0022-0.00220.00550.00720.55410.197626.29---21.75-115.54-30.60--74.7924.09-39.26-293.440.3999--0.1276--14.8255.2122.87--127.36--
Tenax Therapeutics Inc0.00-32.98m14.63m8.00--3.45-----2.03-2.030.000.16840.00----0.00-512.93-130.81-718.76-167.12-----------34,450.780.00-------234.82--12.76--
Health Discovery Corporation0.00-2.91m14.88m3.00---------0.0072-0.00720.00-0.00140.00----0.00-368.63-58.55-3,834.21---------177.68---128.59-----99.93-53.21-148.63------
Data as of May 25 2022. Currency figures normalised to Todos Medical Ltd's reporting currency: US Dollar USD

Institutional shareholders

0.00%Per cent of shares held by top holders
HolderShares% Held
BancFirst (Oklahoma City, Oklahoma) (Investment Management)as of 31 Mar 2022340.00k0.00%
IFP Advisors, Inc.as of 31 Dec 202110.00k0.00%
Data from 31 Dec 2021 - 31 Mar 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.